BiotechTube

Doxorubicin Hydrochloride Liposome Injection

Phase 1UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Cancer

Conditions

Breast Cancer, Ovarian Cancer

Trial Timeline

Jul 28, 2021 → Apr 30, 2022

NCT ID
NCT05273944

About Doxorubicin Hydrochloride Liposome Injection

Doxorubicin Hydrochloride Liposome Injection is a phase 1 stage product being developed by Sun Pharmaceutical for Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05273944. Target conditions include Breast Cancer, Ovarian Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Breast Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved

Hype Score Breakdown

Clinical
6
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05273944Phase 1UNKNOWN

Competing Products

20 competing products in Breast Cancer

See all competitors
ProductCompanyStageHype Score
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
Abemaciclib + FulvestrantEli LillyPhase 2
27
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
39
gemcitabine + vinorelbineEli LillyPhase 2
35
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
26
AbemaciclibEli LillyPre-clinical
26
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
35
arzoxifeneEli LillyApproved
43
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
BBI-940 + FulvestrantBoundless BioPhase 1
26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
pemetrexed + gemcitabineEli LillyPhase 2
35